Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘IDO’

Beyond Loxo’s RET inihibitor, LOXO–292 in RET+ cancers, there were quite a bit of other targeted therapy data to mull over at ASCO this year.

ASCO18 Gems from Poster Halls

We highlighted a few of these in our Preview series in terms of what to watch out for, so I wanted to take a moment and explore some of them in a more detail now that the data have been presented.

Did they live up to the initial promise or not? What can we learn from trial failures? Sometimes this can be even more valuable than positive trials.

To find out, we took a careful at some of the readouts and assessed what looked better or worse than expected to help readers make sense of the tsunami of data that were presented in Chicago.

Inevitably, some of the selections we chose are gems from the poster halls

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Through the window of oncology R&D

With the sad and very gloomy news that Incyte’s IDO inhibitor, epacadostat, has missed in the phase 3 ECHO–301 study in metastatic melanoma, is there still hope for IO-IO combinations in the pipeline?

Here, we take a quick look at the Incyte announcement briefly, but more importantly, we also look forward to other combinations that might be of interest to those following the cancer immunotherapy space.

Not surprisingly, there is a lot to look out for as our sixth post in the AACR18 Preview series highlights as we look through the IO window to potential future developments of interest.

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Killer T cells surround a cancer cell Source: Alex Ritter, Jennifer Lippincott Schwartz & Gillian Griffiths, NIH

With a series of high profile phase 3 cancer immunotherapy combination trials expected to readout throughout 2018, what can we expect given the promise they may offer?

While many people tend to assume that a doublet should produce more efficacy than monotherapy, this isn’t always the case and there’s also the risk of increased toxicities.

That said, are there any hints and learnings we can garner from preclinical and clinical research that might help us assess some of the underlying challenges inherent in these randomised controlled trials?

I say yes there are and here we take a look at a couple of important indicators that may help understand what to expect ahead of time.

To learn more from our conference commentary and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

With the annual meeting of Society for Immunotherapy of Cancer (SITC) fast approaching this week, it’s time for a look at some of the final highlights to watch out for.

National Harbor from Gaylord HotelIn this latest conference preview, we have chosen a dozen key topics of interest that readers may find worth checking out plus an honourable mention for early compounds in development that we may well hear more about going forward.

Some of the early warning signs were offered up in the earlier Previews and with the abstracts now available, things are getting very interesting indeed…

How are things panning out so far with the abstract drop and are the new products in development living up to the hype and expectations?

To learn more insights on the latest Gems from the Poster Hall series, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!